Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 12/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14096508 | 0.84 | ALDH1A1 (0.61) | RAB9ASMN1; SMN2NPC1HPGDTSHR | |
| SCHEMBL14142610 | 0.81 | LMNA (0.80) | RAB9ASMN1; SMN2NPC1HPGDTSHR | |
| SCHEMBL18415485 | 0.81 | POLB (0.72) | RAB9ASMN1; SMN2NPC1HPGDTSHR | |
| SCHEMBL2234130 | 0.81 | HPGD (1.00) | RAB9ASMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL2925459 | 0.81 | NPC1 (0.71) | RAB9ASMN1; SMN2NPC1HPGDTSHR | |
| SCHEMBL7503385 | 0.79 | KDM4E (0.70) | RAB9ASMN1; SMN2NPC1HPGDTSHR | |
| SCHEMBL3561734 | 0.79 | POLB (0.70) | HPGDTSHRALDH1A1HTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL28152221 | 0.79 | HPGD (0.97) | RAB9ASMN1; SMN2NPC1HPGDALDH1A1 | |
| SCHEMBL9401179 | 0.78 | ALDH1A1 (0.59) | RAB9ASMN1; SMN2NPC1HPGDTSHR | |
| SCHEMBL1454563 | 0.78 | POLB (0.73) | RAB9ASMN1; SMN2NPC1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709780-B2 | Integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | 7 HILLS INTERESTS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190351052-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2019-11-14 | — | — | US | disclosed |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS INTERESTS LLC (US) | 2019-07-09 | — | — | US | disclosed |
| CN-107820429-A | Include the new compositions and method for immunization therapy of small molecule integrin receptors ligand activator adjuvant | 7山利益有限责任公司 | 2018-03-20 | — | — | CN | disclosed |
| EP-3288585-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS, LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| CN-106604727-A | Compositions and methods to improve adoptive cell therapies | 7山利益有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| EP-3104867-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS INTERESTS, LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS PHARMA INC. | 2016-11-24 | — | — | US | disclosed |
| WO-2016176400-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS LLC (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015123447-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA, LLC (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | RAB9A 1472/4885SMN1; SMN2 2630/4885NPC1 4131/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | RAB9A 1568/4885SMN1; SMN2 2655/4885NPC1 4132/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | RAB9A 1454/4885SMN1; SMN2 2081/4885NPC1 3036/4885 |
| US-20190351052-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGAM, ITGA2B, ITGA1 | RAB9A 729/4885SMN1; SMN2 2768/4885NPC1 3027/4885 |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGAM, ITGA2B, ITGA2 | RAB9A 1454/4885SMN1; SMN2 2081/4885NPC1 3036/4885 |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | VCAM1, ITGB1, ITGA1 | RAB9A 3744/4885SMN1; SMN2 1141/4885NPC1 1799/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | RAB9A 1429/4885SMN1; SMN2 727/4885NPC1 2875/4885 |
| US-10709780-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | RAB9A 847/4885SMN1; SMN2 2765/4885NPC1 3269/4885 |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGA2B, ITGAM, ITGAV | RAB9A 542/4885SMN1; SMN2 2335/4885NPC1 2793/4885 |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, ICOS, CD274 | RAB9A 1598/4885SMN1; SMN2 2050/4885NPC1 2144/4885 |
| US-20160339098-A1 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, CD274, ICOS | RAB9A 1646/4885SMN1; SMN2 1988/4885NPC1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.